Compare AbbVie Inc (ABBV) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Alphabet Inc Class A — how do they compare? AbbVie Inc trades at $253.2 (market cap $449.91B), while Alphabet Inc Class A trades at $361.2 (market cap $4.46T). The key difference: Alphabet Inc Class A is far larger — about 9.9× AbbVie Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | GOOGL | |
|---|---|---|
Market Cap | $449.91B | $4.46T |
Sector | Health | Media |
52-Week High | $261.07 | $402.62 |
52-Week Low | $184.85 | $174.36 |
Enterprise Value | $513.38B | $4.42T |
Dividend Yield | 2.72% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Alphabet (GOOGL) trades at $360.42, down 1.65% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $402.84B and net income of $132.17B, achieving 37.92% net margins. Recent earnings beats and a $0.22 dividend payment in June 2026 highlight operational strength, while analyst consensus remains overwhelmingly positive with 85% buy ratings.
Alphabet presents a compelling investment case with consistent earnings outperformance and AI-driven growth potential, though investors should monitor regulatory challenges and competitive pressures. The stock trades at a 28 P/E ratio with a $431.35 consensus price target representing 20% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
